Multimodal Brain Monitoring as an Early Warning and Prognostic Tool for Acute Brain Injury

Launched by XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY · Jul 10, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new way to monitor patients with acute brain injuries, like traumatic brain injuries or bleeding in the brain. The goal is to see if special monitoring tools can help doctors detect problems early and improve the care patients receive. By providing timely alerts about a patient's condition, the hope is to prevent complications and better predict how well the patient will recover.

To participate in this trial, individuals must be at least 18 years old and have been diagnosed with specific types of brain injuries. They should also have a certain level of consciousness, as measured by a scale that looks at eye and motor responses. Patients who are admitted to the Intensive Care Unit and meet these criteria may be eligible, while those with severe health issues or other specific conditions may not qualify. This trial is not yet recruiting participants, but it aims to improve outcomes for patients with serious brain injuries by using advanced monitoring techniques.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• • 1. Must be 18 years of age or older.
• • 2. Diagnosed with Traumatic Brain Injury (TBI) or has suffered from acute brain injury due to intracranial hemorrhage or subarachnoid hemorrhage.
• • 3. Defined as an admission Glasgow Coma Scale (GCS) Eye Response score of 1 (unable to open eyes) and a GCS Motor Response score of ≤5 (unable to obey commands).
• • 4. Occurs within 48 hours of admission, where the patient does not open eyes and motor score drops to 5 or below.
• • Exclusion Criteria
• • 1. Patients who were not admitted to the Intensive Care Unit (ICU) are excluded.
• • 2. Patients with forms of acute brain injury other than those specified (TBI, intracranial hemorrhage, subarachnoid hemorrhage) are also excluded.
• • 3. Patients with known severe liver or kidney dysfunction are excluded.
• • 4. Patients whose vital signs are extremely unstable after admission, with a very poor prognosis and considered unable to survive, and whose family has decided to forgo further treatment.
• • 5. Patients who had a Modified Rankin Scale greater than 2 before the onset of the current illness.
• • 6. Patients with a history of congenital or acquired hemorrhagic diseases, coagulation factor deficiencies, or thrombocytopenic disorders.
• • 7. Pregnant or lactating women, as well as those planning to become pregnant within the next 90 days.
• • 8. Patients with severe psychiatric disorders or dementia who are unable to provide informed consent or complete follow-up requirements.
• • 9. Patients who have participated in other interventional clinical trials within 30 days prior to randomization, or who are currently participating in other clinical research.
• • 10. Any other reasons that the researcher deems unsuitable for participation in this trial.